What you could know: -Tempus, a supplier or AI-driven Precision Drugs, and Votingline Therapeutics, Inc. (“Votingline”), A Wholly-owned Subsidiary of the Menarini Group Introduced A New Collaboration to Enhance the Use of ESR1 Testing in Metastatic Breast Most cancers (MBC). -The partnership will use the next Platform from Tempus, an AI-enabled Care Pathway Intelligence Device, to assist clinicians decide when […]
